Communicating Clinical Trial Results: a Not So Bitter Pill to Swallow
February 23, 2005 13:48

After an FDA panel recently recommended that Vioxx could return to the marketplace, investors pushed Merck's stock up 13%. The reason for investor optimism is that this recommendation may limit Merck's legal liability, estimated at as much as $20 billion. ... (Read Article)

Newswise, Wed, 23 Feb 2005 8:22 AM PST
Harvard Health Letter Examines Lessons from the Cox-2 Saga http://www.newswise.com/articles/view/510028/
Newswise — By the beginning of this year, a consensus had developed on the link between COX-2 drugs and heart disease risk: The evidence for cardiovascular side effects was strongest for Vioxx and Bextra, intermediate for Celebrex, and weak for naproxen.